Carabersat

Carabersat

SCHEMBL261192

CC(=O)c1ccc2c(c1)[C@H](NC(=O)c1ccc(F)cc1)[C@@H](O)C(C)(C)O2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ABCC9 O60706 5/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carabersat SCHEMBL29373163 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL9287969 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL27418709 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL3308650 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL3301553 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL3301548 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL3300409 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL27394684 1.00 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL5317948 0.99 ABCC9 (0.64) ABCC9
Carabersat SCHEMBL5317945 0.99 ABCC9 (0.64) ABCC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 688 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3183346-B1 CHANNEL MODULATORS AUCKLAND UNISERVICES LTD (NZ) 2024-10-23 EP claimed
US-10272077-B2 Piperidinone carboxamide azaindane CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2019-04-30 US claimed
US-20180092900-A1 PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2018-04-05 US claimed
EP-3087062-A1 PRODRUG COMPOUNDS Proximagen Limited (GB) 2016-11-02 EP claimed
US-20160016929-A1 PRO-DRUG COMPOUNDS PROXIMAGEN LIMITED 2016-01-21 US claimed
EP-2970226-A1 PRO-DRUG COMPOUNDS Proximagen Limited (GB) 2016-01-20 EP claimed
WO-2015097461-A1 PRODRUG COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-07-02 WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
WO-2014140510-A1 PRO-DRUG COMPOUNDS PROXIMAGEN LIMITED (GB) 2014-09-18 WO claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-6492415-B2 ESPECIALLY FOR TRIGEMINAL NEURALGIA AND NEUROPATHIC PAIN. SMITHKLINE BEECHAM P.L.C. (GB) 2002-12-10 US claimed
EP-0587645-B1 BENZO- AND PYRIDOPYRAN DERIVATIVES HAVING ANXIOLYTIC AND ANTI-CONVULSANT ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2002-02-27 EP claimed
US-20020010209-A1 Use of benzopyranols to treat neurological disorders PARSONS ANDREW (GB) 2002-01-24 US claimed
EP-1108718-A2 Trans-6-Acetyl-4S-(4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol SMITHKLINE BEECHAM PLC (GB) 2001-06-20 EP claimed
US-5889044-A Benzo- and pyridopyran derivatives having anxiolytic and anti-convulsant activity SMITHKLINE BEECHAM P.L.C. (GB) 1999-03-30 US claimed
US-5624954-A Benzo- and pyridopyran derivatives having anxiolytic and anti-convulsant activity SMITHKLINE BEECHAM P.L.C. (GB) 1997-04-29 US claimed
WO-1994012173-A1 BENZOPYRON ANALOGUES FOR THE TREATMENT OF ANXIETY, MANIA, DEPRESSION OR WITHDRAWAL SYMPTOMS SMITHKLINE BEECHAM PLC (GB) 1994-06-09 WO claimed
EP-0126311-B1 BENZOPYRAN DERIVATIVES. BEECHAM GROUP PLC (GB) 1989-09-13 EP claimed
US-4571406-A Anti-hypertensive chromans and chromenes BEECHAM GROUP P.L.C. (GB) 1986-02-18 US claimed
EP-0126311-A2 Benzopyran derivatives. BEECHAM GROUP PLC (GB) 1984-11-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180092900-A1 PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS CALCRL, CALCR, CNR2 ABCC9 1308/4885
US-20020010209-A1 Use of benzopyranols to treat neurological disorders TARDBP, HTT, GRIN3A ABCC9 3301/4885
US-20160016929-A1 PRO-DRUG COMPOUNDS H1-0, ZYX, FURIN ABCC9 103/4885
US-10272077-B2 Piperidinone carboxamide azaindane CGRP receptor antagonists CALCRL, CALCR, CNR2 ABCC9 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.